The Week in Review: September 8 – September 15, 2017

Friday, September 15, 2017 News Recap: President’s Report from HepCBC’s Annual General Meeting (AGM) HepCBC held its Annual General Meeting on September 12, 2017, and we are pleased to note that all the issues that we needed to address were covered.  Rosemary Plummer has stepped down as president after 2 GREAT YEARS of service, but the rest of the Board of Directors has been re-elected, and some very important changes to our Constitution and Bylaws ...

The Week in Review: July 7 – July 14, 2017

Friday, July 14, 2017 News Recap Local New measures boost addiction treatment access in Victoria New efforts to expand treatment for opioid users in Victoria are putting addiction specialists in hospital emergency departments and supporting family doctors who provide opioid substitution therapy for patients. The initiatives by Island Health and the Victoria Divisions of Family Practice are intended to dovetail with the work of the South Island Ra...

Spring Bank Announces Collaboration with Gilead for Hepatitis B (HBV) Phase 2 Study Exploring Combination Treatment of SB 9200 and Vemlidy®

HOPKINTON, Mass., July 10, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases, and certain cancers today announced a second clinical trial collaboration with Gilead Sciences, Inc. for a clinical study examining the use of Spring Bank's oral selective immunomodulator, SB 9200, co-administered with Gilea

Medivir announces that Janssen has initiated an open-label phase IIb study of the 3DAA combination of simeprevir, odalasvir and AL-335 (JNJ-4178)

A phase IIb open-label study of the combination of simeprevir, odalasvir and AL-335, also known as JNJ-4178, has been initiated by Janssen in treatment-naive and treatment-experienced subjects with chronic hepatitis C virus infection without cirrhosis. This global, multi-center study includes clinical trial sites in North America, Europe and Asia and forms part of Janssen’s global development program for JNJ-4178. The objectives of the phase IIb study are

Clinical Trial in Canada by Abbvie is Recruiting

Canada: Effectiveness of Paritaprevir/r – Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada (AMBER) This is an observation study to find out the ‘real world’ effectiveness (cure) of AbbVie’s Holkira Pak (with and without ribavirin) in genotype 1 and 4 patients.  This includes treatment-naïve and treatment experienced patients. AbbVie’s drug combinations are approved by the Food and Drug Administration (FDA) to treat hepat

Regulus Reports Clinical Hold of RG-101

Timelines of On-going Studies are not Expected to be Impacted Conference Call Today at 5:00 p.m. ET LA JOLLA, Calif., June 27, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced it received verbal notice from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) for RG-101 for the t

Biotron Phase 2 Hepatitis C Trial Success

- HCV genotype 1 patients treated with BIT225 and Interferon/Ribavirin (IFN/RBV) significantly more likely to clear virus than those treated with IBN/RBV alone- Major advance in capsule form of BIT225- BIT225 safe and well toleratedNEW YORK, March 17, 2016 /PRNewswire/ -- Biotron Limited (ASX: BIT) confirms positive outcomes from its Phase 2 study of its first-in-class antiviral drug BIT225.The trial was designed to assess the safety and antiviral activity...

Update on TT-034 Hepatitis C Clinical Trial

SYDNEY, Feb. 26, 2016 /PRNewswire/ -- Benitec Biopharma (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) announced today that it will wind-down its hepatitis C program and terminate it upon completion of patients in Cohort 4 in its Phase I/IIa clinical trial for TT-034.Benitec's Board made the decision to discontinue the hepatitis C program following a review of the commercial opportunities for TT-034.  A number of effective therapies have become available for the